Eplontersen + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Conditions
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Trial Timeline
Mar 13, 2020 → Aug 1, 2026
NCT ID
NCT04136171About Eplontersen + Placebo
Eplontersen + Placebo is a phase 3 stage product being developed by AstraZeneca for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). The current trial status is active. This product is registered under clinical trial identifier NCT04136171. Target conditions include Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06194825 | Phase 3 | Active |
| NCT04136171 | Phase 3 | Active |
Competing Products
9 competing products in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 20 |
| ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Nucresiran + Vutrisiran | Alnylam Pharmaceuticals | Phase 3 | 74 |
| ALN-TTRSC04 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |
| Inotersen + Eplontersen | Ionis Pharmaceuticals | Phase 3 | 74 |